NWPF

News ArchivesRead News

New discovery offers hope for Parkinson's

Saturday May 11, 2013

Times of India - Scientists have discovered the three-dimensional structure of the protein Parkin, a finding which may provide new ways to develop drugs to slow the progression of Parkinson's disease.

Researchers from McGill University worked in collaboration with teams led by Dr Edward A Fon at the Montreal Neurological Institute and Hospital - The Neuro, and Dr Kalle Gehring in the Department of Biochemistry at the Faculty of Medicine.

Mutations in Parkin cause a rare hereditary form of Parkinson's disease and are likely to also be involved in more commonly occurring forms of Parkinson's disease.

The Parkin protein protects neurons from cell death due to an accumulation of defective mitochondria. Mitochondria are the batteries in cells, providing the power for cell functions.

This new knowledge of Parkin's structure has allowed the scientists to design mutations in Parkin that make it better at recognising damaged mitochondria and therefore possibly provide better protection for nerve cells.

"The majority of Parkinson's patients suffer from a sporadic form of the disease that occurs from a complex interplay of genetic and environmental factors which are still not fully understood," said Fon, neurologist at The Neuro and head of the McGill Parkinson Programme.

"A minority of patients have genetic mutations in genes such as Parkin that cause the disease. Although there are differences between the genetic and sporadic forms, there is good reason to believe that understanding one will inform us about the other.

"It's known that toxins that poison mitochondria can lead to Parkinson's-like symptoms in humans and animals. Recently, Parkin was shown to be a key player in the cell's system for identifying and removing damaged mitochondria," Fon said.

Gehring likens Parkin to a watchdog for damaged mitochondria.

"Our structural studies show that Parkin is normally kept in check by a part of the protein that acts as a leash to restrict Parkin activity. When we made mutations in this specific 'leash' region in the protein, we found that Parkin recognised damaged mitochondria more quickly," Gehring said.

"If we can reproduce this response with a drug rather than mutations, we might be able to slow the progression of disease in Parkinson's patients," Gehring added.

The research will be published in the journal Science.

Recent News

Aug 24 - Study Details Process Involved in Parkinson’s Disease
Aug 20 - Two proteins work together to help cells eliminate trash; Parkinson's may result
Aug 17 - Scientists visualize critical part of basal ganglia pathways
Aug 17 - VA benefits office seeks all vets exposed to Agent Orange
Aug 12 - New, rapid dementia screening tool rivals 'gold standard' clinical evaluations
Aug 11 - Strolling in Seaside, fighting Parkinson's
Aug 11 - Scientists probing molecular origins of Parkinson's disease highlight two proteins
Aug 11 - Could Chocolate Help To Ease Parkinson’s Disease?
Aug 10 - Take 2: Why Seattle should try to replicate Spokane’s 3-on-3 Hoopfest success
Aug 10 - Book Review: A voyage into Parkinson’s disease, led by patient and journalist
Aug 10 - Parkinson's could be slowed with existing drug
Aug 7 - Opinion: Why modern life is making dementia in your 40s more likely
Aug 3 - Software Turns Smartphones into Tools for Medical Research
Jul 31 - Innovative Technology Using Dragonflies Might Offer Insights Into Human Brain Function
Jul 27 - Low-dose lithium reduces side effects from most common treatment for Parkinson's disease
Jul 27 - Opinion: Parkinson's disease creating class of workers who fear for their jobs: PennLive letters
Jul 22 - Parkinson's: Diabetes drug may offer clue to treatment
Jul 19 - Alzheimer's Drugs in the Works Might Treat Other Diseases, Too
Jul 17 - Parkinson's disease may be treatable with antimalaria drugs
Jul 16 - Virtual research studies feasible